

# Cancer in Manitoba

2015 ANNUAL STATISTICAL REPORT



Department of Epidemiology  
& Cancer Registry

# Department of Epidemiology & Cancer Registry

## Table of Contents

Introduction to the Data	2
Manitoba's Cancer Profile Facts & Figures	3
Most Common Cancers, 2015	3
Cancer Incidence by Site	4
Manitoba Cancer Rates by Regional Health Authority (Incidence)	5
Cancer Incidence - Cases & Rates by Site	6
Tumour Staging by Site	8
Death by Underlying Cause in Manitoba	11
Research: 2015 Publications	12
Appendix 1	14
Department of Epidemiology and Cancer Registry Staff, 2016	15

### **Vision**

Working together, we will reduce the impact of cancer on all Manitobans.

### **Mission**

Through early detection, care, research, education and public outreach, CancerCare Manitoba will contribute to the prevention of cancer and improve the outcomes and quality of life for Manitobans with cancer and blood Disorders.

## Introduction to the Data

The Manitoba Cancer Registry is an essential tool for evidence-based, data-driven decision making that has an immense impact on treatment and research. This year's report is based on the following information.

**NOTE:** *All statistics in the body of this report only include Manitoba residents.*

### Manitoba Cancer Registry data is used for:

- health care planning and monitoring
- surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes and survival
- patient care
- quality assurance
- reporting to the Canadian Cancer Registry, the North American Association of Central Cancer Registries and the International Association of Cancer Registries

### Information sources include:

- provincial cytology and pathology departments
- admission/separation data from the provincial hospital abstracting system
- Manitoba Provincial Client Registry
- letters and "Report of Malignant Neoplasm Forms" from physicians and other health care providers
- hospital health records
- correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in those jurisdictions

### Incidence data

Incidence refers to the number of new cases of cancer diagnosed in Manitoba every year. Cancer cases referenced were diagnosed in the 2015 calendar year. Incidence is also provided by stage of disease at diagnosis.

The Manitoba Cancer Registry uses disease site groupings according to the International Classification of Diseases for Oncology Third Edition (ICD-O3), based on Surveillance Epidemiology and End Results (SEER) Groups. See [Appendix 1](#) for the primary site groupings used for incidence.

### Mortality data

Mortality information refers to Manitobans who died of cancer in the 2015 calendar year, however, those patients may not have been diagnosed in 2015. The Vital Statistics Agency of Manitoba reported cancer as the leading cause of death in the province. In 2015, there were 2,765 deaths due to invasive cancer (age standardized rate – 209.3 per 100,000). The totals in the summary on page 11 include all cancer deaths occurring in Manitoba.

### Rates

Incidence counts and rates are presented in this report. Annual age-standardized rates are per 100,000 population and allow for comparison of cancer rates in different regions with different age structures. Rates are age-standardized (using the direct method) to the 2011 Manitoba population.

### Staging data

The Manitoba Cancer Registry implemented stage data collection for all cases of cancer (excluding non-melanoma skin) diagnosed January 1, 2004 and forward. This data is consistent with the AJCC Cancer Staging Manual, 7th edition.

In this report, stage data is shown for all disease site groups with a cancer incidence of 45 cases per year or more and is represented using pie charts. Stage information, along with frequency of incidence for each of these sites, can also be found in table format on page 9.

### Population data

Data are based on Manitoba estimates provided by Manitoba Health, Seniors and Active Living.

**Additional statistical information is available upon request. Please contact the Manitoba Cancer Registry at:**

**1-877-787-1272 (toll-free) or [CCMBepireg@cancercare.mb.ca](mailto:CCMBepireg@cancercare.mb.ca)**

# Manitoba's Cancer Profile

## Facts & Figures

### Manitoba's cancer profile

Cancer is a significant health issue. In 2015, **11,854** Manitobans were diagnosed with cancer:

- **6,442** invasive cancers
- **4,931** in situ (confined to the area of origin)
- **371** unspecified cancers
- **110** benign brain and CNS (central nervous system)

In this same year, **2,765** people died from the disease.

The number of cancer cases in Manitoba is influenced by three factors:

- the age of the population
- the size of the population
- risk factors such as unhealthy living (including smoking, poor diet, inactivity, sun exposure), some environmental carcinogens, genetic predisposition and not being screened.




## Most Common Cancer Diagnoses, 2015

### Incidence


Male		Female		Total	
SITE	CASES	SITE	CASES	SITE	CASES
Prostate	710	Breast	834	Lung & bronchus	935
Colorectal	482	Lung & bronchus	497	Breast	838
Lung & Bronchus	438	Colorectal	347	Colorectal	829
Non-Hodgkin lymphoma	163	Corpus uteri	262	Prostate	710
Kidney	137	Non-Hodgkin lymphoma	130	Non-Hodgkin lymphoma	293
Melanoma of the skin	131	Melanoma of the skin	110	Corpus uteri	262
Bladder	105	Thyroid	98	Melanoma of the skin	241
Stomach	84	Kidney	94	Kidney	231
Pancreas	78	Pancreas	93	Pancreas	171
Chronic lymphocytic leukemia	59	Ovary	84	Bladder	147

# Cancer Incidence by Site

## Invasive cancers only



## Manitoba Cancer Rates by Regional Health Authority



### All Invasive Cancers Female Incidence

Age-standardized rate per 100,000

Standard population: Manitoba 2011


Out of province residents excluded

### All Invasive Cancers Male Incidence

Age-standardized rate per 100,000

Standard population: Manitoba 2011

Out of province residents excluded



# Cancer Incidence - Cases and Rates in Manitoba by Site, 2015

	Cancer Site	Age group																		Total Count			ASIR*					
		00-29			30-39			40-49			50-59			60-69			70-79			80+			M	F	T	M	F	T
		M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T			
Buccal cavity & pharynx	Lip	0	0	0	0	0	0	0	0	0	5	0	5	8	2	10	10	2	12	10	1	11	33	5	38	5.47	0.66	2.78
	Tongue	0	0	0	3	0	3	2	1	3	5	7	12	11	3	14	10	6	16	0	4	4	31	21	52	4.61	2.94	3.80
	Major salivary gland	0	0	0	1	0	1	0	0	0	0	1	1	1	3	4	0	0	0	0	3	3	2	7	9	0.29	0.93	0.66
	Floor of mouth	0	0	0	0	0	0	1	0	1	1	1	2	4	0	4	3	0	3	0	0	0	9	1	10	1.34	0.15	0.73
	Gum & other mouth	0	0	0	0	0	0	1	1	2	3	0	3	4	2	6	3	0	3	0	0	0	11	3	14	1.64	0.44	1.02
	Nasopharynx	0	0	0	0	0	0	1	1	2	3	1	4	1	3	4	0	0	0	0	0	0	5	5	10	0.76	0.72	0.74
	Oropharynx	0	0	0	0	0	0	0	0	0	2	1	3	1	1	2	0	0	0	1	0	1	4	2	6	0.65	0.29	0.44
	Hypopharynx	0	0	0	0	0	0	0	0	0	2	0	2	5	1	6	0	0	0	1	1	2	8	2	10	1.21	0.26	0.72
	Other buccal cavity & pharynx	0	0	0	0	0	0	2	0	2	9	1	10	5	1	6	1	0	1	2	2	4	19	4	23	2.96	0.53	1.72
Digestive	Esophagus	0	0	0	0	0	0	0	1	1	7	4	11	11	4	15	18	3	21	8	2	10	44	14	58	7.01	1.97	4.23
	Stomach	0	1	1	0	0	0	3	3	6	13	7	20	16	7	23	23	10	33	29	20	49	84	48	132	14.21	6.50	9.83
	Small intestine	0	0	0	1	0	1	1	0	1	1	3	4	7	3	10	4	2	6	2	3	5	16	11	27	2.47	1.50	1.96
	Colon excluding rectum	3	4	7	10	5	15	8	12	20	48	27	75	70	44	114	76	54	130	67	80	147	282	226	508	45.77	30.61	37.53
	Rectum & rectosigmoid	2	0	2	3	3	6	15	12	27	44	25	69	52	26	78	50	27	77	34	28	62	200	121	321	31.84	16.87	23.76
	Anus	0	0	0	0	0	0	1	1	2	3	4	7	3	5	8	2	4	6	1	1	2	10	15	25	1.55	2.11	1.83
	Liver	0	0	0	0	0	0	2	0	2	10	5	15	24	5	29	14	4	18	4	1	5	54	15	69	8.18	2.10	4.98
	Gallbladder	0	0	0	0	0	0	0	0	0	1	2	3	4	7	11	2	6	8	1	5	6	8	20	28	1.22	2.68	2.02
	Pancreas	0	1	1	0	0	0	0	4	4	10	7	17	31	13	44	26	27	53	11	41	52	78	93	171	12.11	12.38	12.55
	Other digestive system	0	0	0	0	0	0	4	3	7	6	6	12	7	7	14	7	11	18	10	10	20	34	37	71	5.69	5.09	5.30
Respiratory	Larynx	0	0	0	0	0	0	0	0	0	5	2	7	13	1	14	6	2	8	3	0	3	27	5	32	4.12	0.71	2.30
	Lung & bronchus	1	0	1	0	0	0	5	7	12	47	65	112	138	149	287	149	162	311	98	114	212	438	497	935	70.48	67.18	68.04
	Other respiratory system	1	0	1	1	0	1	0	0	0	2	3	5	1	1	2	1	0	1	1	1	2	7	5	12	1.10	0.71	0.89
	Bones & joints	1	1	2	0	1	1	1	0	1	1	0	1	1	1	2	0	1	1	0	0	0	4	4	8	0.61	0.57	0.59
Mesothelial & Soft tissue (including heart)	Soft tissue (Including heart)	2	5	7	2	1	3	3	1	4	7	3	10	3	5	8	5	4	9	6	2	8	28	21	49	4.57	3.01	3.66
	Kaposi sarcoma	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	2	0	2	0	0	0	3	0	3	0.45	0.00	0.22
	Mesothelioma	0	0	0	0	0	0	0	0	0	1	1	2	4	1	5	5	2	7	4	3	7	14	7	21	2.30	0.93	1.54
	Melanoma of the skin	0	4	4	4	4	8	8	17	25	26	24	50	37	25	62	36	19	55	20	17	37	131	110	241	20.67	15.75	17.84
	Breast	0	2	2	0	34	34	0	93	93	0	184	184	0	240	240	1	162	163	3	119	122	4	834	838	0.77	117.79	61.98

Cancer Site	Age group																								Total Count			ASIR*		
	00-29			30-39			40-49			50-59			60-69			70-79			80+											
	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T			
Female genital	Cervix uteri		4			9			12			7			5			1			1			39			5.94			
	Corpus uteri		3			9			31			68			87			40			24			262			37.41			
	Uterus, NOS		0			0			0			2			2			0			2			6			0.82			
	Ovary		3			0			12			22			20			15			12			84			12.03			
	Other female genital system		0			1			2			9			9			11			7			39			5.42			
Male genital	Prostate	0			0			8			86			256			246			114			710			111.44				
	Testis	13			11			6			8			1			0			1			40			6.12				
	Penis	0			1			0			4			6			8			1			20			3.03				
	Other male genital system	0			0			0			1			0			0			0			1			0.15				
Urinary	Bladder	0	0	0	0	0	0	2	1	3	14	2	16	29	7	36	32	11	43	28	21	49	105	42	147	17.19	5.50	10.82		
	Kidney	1	2	3	5	0	5	13	9	22	33	14	47	49	28	77	19	22	41	17	19	36	137	94	231	21.31	13.05	17.01		
	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	2	2	2	4	4	3	7	0.71	0.38	0.52		
	Other urinary system	0	0	0	0	0	0	0	0	0	3	0	3	0	1	1	2	2	4	4	0	4	9	3	12	1.58	0.41	0.89		
Eye	0	2	2	0	1	1	0	0	0	2	0	2	1	0	1	2	0	2	0	2	2	5	5	10	0.75	0.71	0.75			
Brain & other CNS	Brain	8	7	15	3	1	4	5	3	8	11	9	20	7	9	16	6	6	12	0	5	5	40	40	80	6.03	5.76	5.97		
	Other nervous system	2	0	2	0	0	0	0	1	1	1	1	2	0	0	0	1	0	1	0	0	0	4	2	6	0.60	0.32	0.46		
Endocrine	Thyroid	2	8	10	5	16	21	9	26	35	10	20	30	12	17	29	4	7	11	0	4	4	42	98	140	6.34	14.71	10.59		
	Other endocrine	7	1	8	0	0	0	0	0	0	0	0	0	1	0	1	0	2	2	0	1	1	8	4	12	1.19	0.55	0.90		
Lymphoma	Hodgkin lymphoma	4	4	8	3	6	9	1	3	4	1	0	1	6	1	7	3	2	5	1	3	4	19	19	38	2.87	2.78	2.83		
	Non-Hodgkin lymphoma	3	3	6	9	2	11	12	5	17	24	25	49	50	36	86	42	25	67	23	34	57	163	130	293	25.59	17.84	21.53		
	Multiple myeloma	0	0	0	1	3	4	3	0	3	10	5	15	16	13	29	15	10	25	9	7	16	54	38	92	8.55	5.17	6.71		
Leukemias	Acute lymphocytic leukemia	8	4	12	0	1	1	0	0	0	1	2	3	2	0	2	0	1	1	1	1	2	12	9	21	1.83	1.34	1.58		
	Chronic lymphocytic leukemia	0	0	0	0	0	0	4	1	5	9	6	15	18	12	30	19	10	29	9	5	14	59	34	93	9.32	4.67	6.78		
	Acute myeloid leukemia	3	1	4	1	0	1	2	3	5	4	4	8	5	3	8	10	3	13	5	4	9	30	18	48	4.80	2.57	3.58		
	Chronic myeloid leukemia	2	1	3	1	0	1	1	1	2	1	1	2	1	1	2	4	3	7	3	4	7	13	11	24	2.14	1.51	1.80		
	Acute monocytic leukemia	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	1	2	0.15	0.16	0.15		
	Other leukemias	0	0	0	0	0	0	2	1	3	1	2	3	0	2	2	1	1	2	2	1	3	6	7	13	1.05	1.00	0.99		
Other, ill defined & unknown	5	2	7	2	0	2	4	4	8	11	14	25	35	20	55	42	35	77	34	43	77	133	118	251	21.73	15.87	18.52			
TOTAL - ALL INVASIVE	68	64	132	68	97	165	130	272	402	497	597	1094	958	833	1791	912	716	1628	570	660	1230	3203	3239	6442	508.49	451.31	473.83			
In situ	Non-Melanoma skin & in situ skin	4	11	15	22	32	54	98	114	212	264	280	544	509	409	918	581	392	973	550	495	1045	2028	1733	3761	333.82	237.49	277.85		
	Breast in situ	0	0	0	0	6	6	0	7	7	0	27	27	0	43	43	0	21	21	0	9	9	0	113	113	0.00	15.90	8.23		
	Cervix in situ		167			107			48			20			11			2			2			357	357		54.83			
	Prostate in situ	0			1			0			3			18			8			0			30		30	4.35				
	Bladder in situ	1	1	2	1	0	1	1	2	3	17	5	22	33	11	44	43	18	61	34	8	42	130	45	175	21.26	6.16	12.80		
	Colorectal in situ	1	2	3	1	3	4	13	9	22	54	34	88	75	37	112	62	46	108	28	18	46	234	149	383	36.4	20.87	28.04		
	Other in situ (Excl. Breast, Skin, Cervix, Prostate, Bladder, Colorectal)	0	3	3	1	4	5	1	14	15	12	12	24	16	13	29	10	10	20	5	11	16	45	67	112	6.93	9.69	8.33		
TOTAL - INVASIVE & IN SITU	74	248	322	94	249	343	243	466	709	847	975	1822	1609	1357	2966	1616	1205	2821	1187	1203	2390	5670	5703	11373	911.24	796.26	838.39			
Brain uncertain & unspecified	Brain uncertain & unspecified	1	1	2	0	0	0	1	1	2	4	0	4	1	3	4	0	2	2	1	2	3	8	9	17	1.26	1.25	1.27		
	Neoplasms (Uncertain & unspecified, excluding brain)	9	12	21	10	10	20	11	20	31	27	33	60	33	39	72	48	31	79	36	35	71	174	180	354	28.13	25.48	26.32		
	Brain & nervous system benign	3	2	5	6	6	12	4	5	9	8	14	22	9	13	22	5	12	17	8	15	23	43	67	110	6.88	9.39	8.19		
ALL CANCERS	87	263	350	110	265	375	259	492	751	886	1022	1908	1652	1412	3064	1669	1250	2919	1232	1255	2487	5895	5959	11854	947.52	832.37	874.18			

Age-standardized incidence rate per 100,000  
Standard population: Manitoba 2011




## Staging on sites with more than 45 cases

(Invasive cancers only)

### Esophagus

	Frequency	Percent	
Stage I	12	20.7	
Stage II	7	12.1	
Stage III	17	29.3	
Stage IV	16	27.6	
Unknown	6	10.3	
<b>Total</b>	<b>58</b>	<b>100</b>	



### Stomach

	Frequency	Percent	
Stage I	22	16.7	
Stage II	25	18.9	
Stage III	19	14.4	
Stage IV	44	33.3	
Unknown	22	16.7	
<b>Total</b>	<b>132</b>	<b>100</b>	




### Colon excluding rectum

	Frequency	Percent	
Stage I	111	21.9	
Stage II	156	30.7	
Stage III	118	23.2	
Stage IV	107	21.1	
Unknown	16	3.2	
<b>Total</b>	<b>508</b>	<b>100</b>	




### Rectum & rectosigmoid

	Frequency	Percent	
Stage I	71	22.1	
Stage II	43	13.4	
Stage III	134	41.7	
Stage IV	61	19.0	
Unknown	12	3.7	
<b>Total</b>	<b>321</b>	<b>100</b>	




### Liver

	Frequency	Percent	
Stage I	16	23.2	
Stage II	17	24.6	
Stage III	10	14.5	
Stage IV	10	14.5	
Unknown	16	23.2	
<b>Total</b>	<b>69</b>	<b>100</b>	




### Pancreas

	Frequency	Percent	
Stage I	11	6.4	
Stage II	43	25.2	
Stage III	13	7.6	
Stage IV	89	52.1	
Unknown	15	8.8	
<b>Total</b>	<b>171</b>	<b>100</b>	




### Other digestive system

	Frequency	Percent	
Stage I	11	15.5	
Stage II	8	11.3	
Stage III	7	9.9	
Stage IV	16	22.5	
Unknown	29	40.9	
<b>Total</b>	<b>71</b>	<b>100</b>	




### Lung & bronchus

	Frequency	Percent	
Stage I	219	23.4	
Stage II	77	8.2	
Stage III	197	21.1	
Stage IV	432	46.2	
Unknown	8	0.9	
Occult	2	0.2	
<b>Total</b>	<b>935</b>	<b>100</b>	




## Melanoma of the skin

	Frequency	Percent	
Stage I	169	70.1	
Stage II	40	16.6	
Stage III	14	5.8	
Stage IV	14	5.8	
Unknown	4	1.7	
<b>Total</b>	<b>241</b>	<b>100</b>	




## Breast

	Frequency	Percent	
Stage I	392	46.8	
Stage II	284	33.9	
Stage III	102	12.2	
Stage IV	52	6.2	
Unknown	8	1.0	
<b>Total</b>	<b>838</b>	<b>100</b>	




## Corpus uteri

	Frequency	Percent	
Stage I	189	72.1	
Stage II	22	8.4	
Stage III	34	13.0	
Stage IV	10	3.8	
Unknown	7	2.7	
<b>Total</b>	<b>262</b>	<b>100</b>	




## Ovary

	Frequency	Percent	
Stage I	22	26.2	
Stage II	7	8.3	
Stage III	33	39.3	
Stage IV	17	20.2	
Unknown	5	6.0	
<b>Total</b>	<b>84</b>	<b>100</b>	




## Prostate

	Frequency	Percent	
Stage I	79	11.1	
Stage II	430	60.6	
Stage III	72	10.1	
Stage IV	119	16.8	
Unknown	10	1.4	
<b>Total</b>	<b>710</b>	<b>100</b>	




## Bladder

	Frequency	Percent	
Stage I	60	40.8	
Stage II	37	25.2	
Stage III	14	9.5	
Stage IV	31	21.1	
Unknown	5	3.4	
<b>Total</b>	<b>147</b>	<b>100</b>	




## Kidney

	Frequency	Percent	
Stage I	117	50.7	
Stage II	16	6.9	
Stage III	53	22.9	
Stage IV	39	16.9	
Unknown	6	2.6	
<b>Total</b>	<b>231</b>	<b>100</b>	




## Thyroid

	Frequency	Percent	
Stage I	84	60.0	
Stage II	20	14.3	
Stage III	19	13.6	
Stage IV	17	12.1	
Unknown	0	0.0	
<b>Total</b>	<b>140</b>	<b>100</b>	




### Non-Hodgkin lymphoma

	Frequency	Percent
Stage I	62	21.2
Stage II	53	18.1
Stage III	66	22.5
Stage IV	109	37.2
Unknown	3	1.0
<b>Total</b>	<b>293</b>	<b>100</b>




### Tongue

	Frequency	Percent
Stage I	14	26.9
Stage II	9	17.3
Stage III	5	9.6
Stage IV	24	46.2
Unknown	0	0.0
<b>Total</b>	<b>52</b>	<b>100</b>



### Soft tissue (Including heart)

	Frequency	Percent
Stage I	23	46.9
Stage II	10	20.4
Stage III	9	18.4
Stage IV	6	12.2
Unknown	1	2.0
<b>Total</b>	<b>49</b>	<b>100</b>



*\*In keeping with international coding conventions, all invasive brain tumours, multiple myeloma and leukemia are considered unstageable using the collaborative staging system utilized by all population-based North American Cancer Registries.*

## Deaths by Underlying Cause in Manitoba

(Rate per 100,000)

CAUSES OF DEATH	2015			2014			2013		
	AMOUNT	Rate per MB Health Population	Rate per Statistics Canada Population	AMOUNT	Rate per MB Health Population	Rate per Statistics Canada Population	AMOUNT	Rate per MB Health Population	Rate per Statistics Canada Population
Accidents (V01-X59, Y85-Y86)	534	40.4	41.3	526	40.3	41.0	515	39.9	40.8
<b>Cancer (C00-C97)</b>	<b>2765</b>	<b>209.3</b>	<b>213.7</b>	<b>2886</b>	<b>220.9</b>	<b>225.1</b>	<b>2,673</b>	<b>207.3</b>	<b>212.0</b>
Cerebrovascular Disease (I60-I69)	596	45.1	46.1	651	49.8	50.8	608	47.2	48.2
Diabetes (E10-E14)	368	27.9	28.5	324	24.8	25.3	339	26.3	26.9
Diseases of the heart (I00-I09, I11, I13, I20-I25, I26-I51)	2136	161.8	165.1	2217	169.7	172.9	2076	161.0	164.6
Pneumonia (J12-J18)	228	17.3	17.6	226	17.3	17.6	220	17.1	17.4
Suicide (X60-X84, Y890)	173	13.1	13.4	176	13.5	13.7	158	12.3	12.5

### Reference

<sup>1</sup> Vital Statistics Agency, 2015/16 Annual Report. Government of Manitoba; 2016. [cited Aug 8, 2017].

[http://vitalstats.gov.mb.ca/pdf/2016\\_vs\\_annual\\_report\\_en.pdf](http://vitalstats.gov.mb.ca/pdf/2016_vs_annual_report_en.pdf)

## 2015 Publications using Department of Epidemiology and Cancer Registry

(staff names of those presently employed in the Department and/or employed at the time research was undertaken are in bold)

- (1) CancerCare Manitoba 2013-14 Community Health Assessment. 2015.
- (2) Ahmed S, Neufeld S, Krocak TJ, Bashir B, Ahmed N, Czaykowski P, et al. Small Cell Cancer of the Bladder and Prostate: A Retrospective Review from a Tertiary Cancer Centre. *Cureus* 7(8): e296 2015.
- (3) Ahmed N, Lobchuk M, Hunter WM, Johnston P, **Nugent Z**, Sharma A, et al. How, When and Where to Discuss Do Not Resuscitate: A Prospective Study to Compare the Perceptions and Preferences of Patients, Caregivers, and Health Care Providers in a Multidisciplinary Lung Cancer Clinic. *Cureus* 2015;7:e257.
- (4) Ahmed N, Lobchuk M, Hunter WM, Johnston P, **Nugent Z**, Sharma A, et al. Perceptions and Preferences of Patients with Terminal Lung Cancer and Family Caregivers about DNR. *Cureus* 2015;7:e271.
- (5) Alsubaie H, **Leggett C**, **Lambert P**, Park J, Hochman D, Wirtzfeld D, et al. Diagnosis of VTE postdischarge for major abdominal and pelvic oncologic surgery: implications for a change in practice. *Can J Surg* 2015;58:305-11.
- (6) Alwazzan AB, Popowich S, Dean E, Robinson C, Lotocki R, Altman AD. Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center. *Int J Gynecol Cancer* 2015.
- (7) Cisyk AL, Penner-Goeke S, Lichtensztein Z, **Nugent Z**, Wightman RH, Singh H, et al. Characterizing the Prevalence of Chromosome Instability in Interval Colorectal Cancer. *Neoplasia* 2015;17:306-16.
- (8) **Decker KM**, **Demers AA**, **Kliewer EV**, **Biswanger N**, **Musto G**, Elias B, et al. Pap test use and cervical cancer incidence in First Nations women living in Manitoba. *Cancer Prev Res (Phila)* 2015;8:49-55.
- (9) **Decker KM**, McLachlin CM, Lotocki R. Performance measures related to colposcopy for canadian cervical cancer screening programs: identifying areas for improvement. *J Obstet Gynaecol Can* 2015;37:245-51.
- (10) **Decker KM**, **Demers AA**, **Kliewer EV**, **Musto G**, **Shu E**, **Biswanger N**, et al. Colorectal cancer screening in first nations people living in Manitoba. *Cancer Epidemiol Biomarkers Prev* 2015;24:241-8.
- (11) **Decker KM**, **Demers AA**, **Nugent Z**, **Biswanger N**, Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. *Am J Gastroenterol* 2015;110:1640-6.
- (12) **Demers AA**, **Decker KM**, **Kliewer EV**, **Musto G**, **Shu E**, **Biswanger N**, et al. Mammography rates for breast cancer screening: a comparison of First Nations women and all other women living in Manitoba, Canada, 1999-2008. *Prev Chronic Dis* 2015;12:E82.
- (13) Department of Epidemiology and Cancer Registry. *Cancer in Manitoba 2013 Annual Statistical Report*. 2015.
- (14) Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. *Lancet Infect Dis* 2015;15:565-80.
- (15) Harlos C, **Musto G**, **Lambert P**, **Ahmed R**, Pitz MW. Androgen pathway manipulation and survival in patients with lung cancer. *Horm Cancer* 2015;6:120-7.
- (16) Harlos CH, Pitz M, **Musto G**. Androgen deprivation therapy and survival in patients with lung cancer. *Horm Cancer* 2015;accepted for publication.
- (17) Hendrickson-Rebizant J, Sigvaldason H, Nason RW, Pathak KA. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer. *Eur J Surg Oncol* 2015.

- (18) Kang YJ, O'Connell DL, Tan J, Lew JB, **Demers A**, Lotocki R, et al. Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities. *Cancer Epidemiol* 2015;39:600-11.
- (19) Kang YJ, O'Connell DL, Lotocki R, **Kliewer EV**, Goldsbury DE, **Demers AA**, et al. Effect of changes in treatment practice on survival for cervical cancer: results from a population-based study in Manitoba, Canada. *BMC Cancer* 2015;15:642.
- (20) Kerr P, Myers CL, Butler J, Alessa M, **Lambert P**, Cooke AL. Prospective functional outcomes in sequential population based cohorts of stage III/ IV oropharyngeal carcinoma patients treated with 3D conformal vs. intensity modulated radiotherapy. *J Otolaryngol Head Neck Surg* 2015;44:17.
- (21) Major D, Armstrong D, Bryant H, Cheung W, **Decker K**, Doyle G, et al. Recent trends in breast, cervical, and colorectal cancer screening test utilization in Canada, using self-reported data from 2008 and 2012. *Curr Oncol* 2015;22:297-302.
- (22) Neumann K, Mahmud SM, McKay A, Park J, Metcalfe J, Hochman DJ. Is obesity associated with advanced stage or grade of colon cancer? *Can J Surg* 2015;58:004414.
- (23) Pan SY, Mao Y, Ugnat AM, Canadian Cancer Registries Epidemiology Research Group. Physical activity, obesity, energy intake, and the risk of non-Hodgkin's lymphoma: a population-based case-control study. *Am J Epidemiol* 2015;162:1162-73.
- (24) Quon H, Myers C, **Lambert P**, Butler J, Abdoh A, Stimpson R, et al. Impact of feeding tubes on prospective functional outcomes in patients with locally advanced head and neck cancer undergoing radiation therapy. *Pract Radiat Oncol* 2015.
- (25) Singh H, Bernstein CN, Samadder JN, **Ahmed R**. Screening rates for colorectal cancer in Canada: a cross-sectional study. *CMAJ Open* 2015;3:E149-E157.
- (26) Stevic I, Dembinski TC, Pathak KA, Leslie WD. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer. *Clin Biochem* 2015.
- (27) Torabi M, Singh H, **Galloway K**, Israels SJ. Geographical variation in the incidence of childhood leukaemia in Manitoba. *J Paediatr Child Health* 2015.
- (28) Zakaria D, Trudeau R, Sanmartin C, Murison P, Carriere G, MacIntyre M, et al. Using personal health insurance numbers to link the Canadian Cancer Registry and the Discharge Abstract Database. *Health Rep* 2015;26:3-11.

# Appendix 1

## INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY

### 3rd Edition

PRIMARY SITE	SITE/ CELL TYPE	PRIMARY SITE	SITE/ CELL TYPE
<b>Buccal cavity and pharynx</b>	C00:C14	<b>Male genital system</b>	C60:C63
Lip	C000:C009	Prostate	C619
Tongue	C019:C029	Testis	C620:C629
Major salivary gland	C079:C089	Penis	C600:C609
Floor of mouth	C040:C049	Other male genital system	C630:C639
Gum & other mouth	C030:C039, C050:C059, C060:C069	<b>Urinary system</b>	C64:C68
Nasopharynx	C110:C119	Bladder (incl. in situ)	C670:C679
Oropharynx	C100:C109	Kidney and renal pelvis	C649, C659
Hypopharynx	C129, C130:C139	Ureter	C669
Other buccal cavity &	C090:C099, C140, C142:C148	Other urinary system	C680:C689
<b>Digestive system</b>	C15:C26	<b>Eye</b>	C690:C699
Esophagus	C150:C159	<b>Brain &amp; other nervous system</b>	C70:C72
Stomach	C160:C169	Brain	C710:C719
Small intestine	C170:C179	Other nervous system	C710:C719 ( 953), C700:C709, C720:C729
Colon excluding rectum	C180:C189, C260	<b>Endocrine</b>	C73:C75
Rectum & Rectosigmoid	C199, C209	Thyroid	C739
Anus	C210:C212, C218	Other endocrine	C379, C740:C749, C750:C759
Liver	C220	<b>Lymphomas</b>	
Gallbladder	C239	Hodgkin lymphoma	9650-9667
Pancreas	C250:C259	Non-Hodgkin lymphoma	9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737, 9738
Other digestive system	C240:C249, C221, C480, C481:C482, C268:C269, C488		9811-9818 (except C420, C421, C424)
<b>Respiratory system</b>	C30:C39		9823 (except C420, C421, C424)
Larynx	C320:C329		9827 (except C420, C421, C424)
Lung & bronchus	C340:C349		9837 (except C420, C421, C424)
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383, C388, C390:C399		
<b>Bones &amp; joints</b>	C400:C419	Myeloma	9731-9732, 9734
<b>Soft tissue (including heart)</b>	C380, C470:C479, C490:C499	<b>Leukemias</b>	C42
<b>Mesothelioma</b>	9050:9055	Acute lymphocytic	9826, 9835-9836
<b>Kaposi sarcoma</b>	9140		9811-9818 (only C421)
<b>Skin</b>	C44		9837 (only C421)
Melanomas of the skin	C440:C449 ( 8720:8790)	Chronic lymphocytic	9823 (only C421, if SLL C77)
Other skin	C440:C449	Acute myeloid	9840, 9861, 9865-9867, 9869, 9871-9874, 9895-9897, 9898, 9910-9911, 9920,
<b>Breast</b>	C500:C509		9891
<b>Female genital system</b>	C51:C58	Acute monocytic	9863, 9875-9876, 9945-9946
Cervix uteri	C530:C539	Chronic myeloid	9733, 9742, 9800, 9801, 9805-9809, 9820, 9831-9834, 9860, 9870, 9930, 9931, 9940, 9948, 9963, 9964
Corpus uteri	C540:C549	Other	9827 (only C421)
Uterus, NOS	C559		
Ovary	C569	<b>Other, ill-defined, &amp; unknown</b>	9740-9741, 9750-9769, 9950, 9960-9962, 9965-9967, 9970-9971, 9975, 9980, 9982-9987, 9989, 9991-9992
Other female genital system	C529, C510:C519, C570:C589		C420-C424 (except 9050-9055, 9140, 9590-9992)
			C760-C768 (except 9050-9055, 9140, 9590-9992)
			C770-C779 (except 9050-9055, 9140, 9590-9992)
			C809 (except 9050-9055, 9140, 9590-9992)

## 2017 Department of Epidemiology and Cancer Registry Staff

### Donna Turner, PhD

PROVINCIAL DIRECTOR  
POPULATION ONCOLOGY

### Gail Noonan, CTR

MANAGER  
MANITOBA CANCER REGISTRY

### Al Artaman MD, PhD, MHA

DIRECTOR  
EPIDEMIOLOGY

#### CANCER REGISTRARS

Jennifer Cadger, HIT

Danielle Chalmers, CHIM, CTR

Angela Deneka, HIT

Sheila Fukumura, CTR  
SENIOR CANCER REGISTRAR

Sara Gray, CHIM, CTR  
SENIOR QUALITY CONTROL COORDINATOR

Terri-Lee Handel, CTR

Coreen Hildebrand, CTR

Sharon Lawrence, HIT

Loriann Love, HIT

Joanna Panganiban, CHIM

Bree-Anne Rydzygowski, HIM

Margaret Schroeder, HIM

Melissa Scott, CHIM, CTR  
SENIOR EDUCATION COORDINATOR

Thais Souza, CHIM

#### EPIDEMIOLOGISTS

Oliver Bucher, MSc

Kathleen Decker, PhD

Dorian Murariu, MSc

Donna Turner, PhD

#### HEALTH OUTCOMES ANALYSTS

Pascal Lambert, MSc

Charlene Muzyka, MSc

#### BIOSTATISTICIAN

Rajib Mian, PhD

#### STUDY COORDINATORS

Cyndi Fraser, BEd

Elizabeth Harland, MA

Iresha Ratnayake, BSc

#### CANCER RESEARCH & EVALUATION COORDINATOR

Carrie O'Conaill, MPH

#### PROGRAMMER ANALYSTS

Zeb Aurangzeb, PhD

Natalie Biswanger, BSc

Jenniebie Bravo, MSc

Katie Galloway, MSc

Grace Musto, BSc

Mary Natividad, BSc

Alexander Sachs, BComm

Lin Xue, MSc

#### PROJECT MANAGER

Cheryl Clague, CHIM

#### ADMINISTRATIVE ASSISTANT

Karen Carson-Walton



---

## CONTACT DETAILS

## TO CITE THIS REPORT

Department of Epidemiology and Cancer Registry, CancerCare Manitoba.

“Cancer in Manitoba, 2015 Annual Statistical Report.”

Find the Department of Epidemiology and Cancer Registry and data request guidelines online under the Research tab at [www.cancercare.mb.ca](http://www.cancercare.mb.ca)

---